Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemaphor has announced that its project 'Natural, Non-Antibiotic Products Enhancing Food-Animal Products' has been selected to receive Share of Government of Canada Investment in R&D.
Subscribe to our email newsletter
Research and development across Atlantic Canada is benefiting from an important federal investment of $62.4m, under Round VII of the Atlantic Innovation Fund (AIF). Reportedly, in the island, a total of seven R&D projects, representing both private and public sector research, will benefit from $12.3m in AIF support in this round.
The announcement is part of a series of announcements highlighting 30 innovative R&D projects selected from across Atlantic Canada, that will benefit from AIF support available under Round VII of the program.
Keith Ashfield, minister of National Revenue, Atlantic Canada Opportunities Agency (ACOA), and Atlantic Gateway, said: “We are investing in realistic and achievable projects. Projects that will advance our innovation and knowledge capacity, generate a range of alternative technologies, and develop leading-edge products and processes.”
ACOA’s Atlantic Innovation Fund encourages the commercialization of research in Atlantic Canada and has been a key driver for many Atlantic Canadian businesses, universities and research institutions.
The Chemaphor project is based on the development of OxBC, a natural carotenoid oxidation product with the demonstrated ability to enhance the immune system of animals. In this project, Chemaphor will evaluate OxBC as a natural means of improving livestock immune systems, in turn reducing the need for antibiotics. Based on the announcement, this project, with total estimated costs of $3.8m, is anticipated to receive approximately $2m from the Atlantic Innovation Fund over a three-year period.
Paul Dick, CEO of Chemaphor, said: “We are delighted and gratified that our project has been selected for continued support from the AIF. The existing support from AIF has been critical to the set-up and development of our biological R&D operation in Charlottetown, which in turn has provided the Company with an important innovative edge in the development of novel wellness products for animal health. The new support from the AIF will be of major help in allowing Chemaphor to continue its development of products that are slated for commercialization in companion animal and food production animal markets.”